• 10 October, 2019
  • The ISSCR submitted comments to Brazil’s health regulatory agency (ANVISA) regarding the proposed regulations for advanced therapy medicinal products that urge national governments to “maintain rigorous review pathways to ensure that stem cell-based products conform to the highest standards of evidence-based medicine.”
    Full story
  • 12 August, 2019
  • The International Society for Stem Cell Research (ISSCR) today released a professional standard of informed consent for stem cell-based interventions performed outside of formal clinical trials, such as the unapproved and unproven “treatments” offered by clinicians at direct-to-consumer clinics. The standard is meant to help ensure that patients are informed about the potential benefits and risks of stem cell-based medical interventions, and was developed with input from clinicians, ethicists, researchers, and regulators from around the world.
    Full story
  • 7 June, 2019
  • The ISSCR commends the U.S. District Court ruling that confirms the FDA’s authority to regulate clinics marketing and selling unproven therapies as stem cell products. The clinic, U.S. Stem Cell, has injected cells derived from fat into the eyes of several patients, resulting in at least three being blinded.
    Full story
  • 5 June, 2019
  • The International Society for Stem Cell Research (ISSCR), the largest professional organization of stem cell researchers from around the world, opposes the new U.S. Health and Human Services policy to eliminate federal funding for fetal tissue research in the National Institutes of Health (NIH) intramural research program. This research has long been viewed as good public policy to improve human health and has proceeded with public support.
    Full story
  • ISSCR Commends U.S. House of Representatives Committee for Approval of NIH Funding Bill

  • 10 May, 2019
  • The Appropriations Committee of the U.S. House of Representatives has approved a $2 billion increase for the National Institutes of Health (NIH) and defeated an amendment that would have prohibited federal funding for fetal tissue research.
    Full story
  • ISSCR Comments on New Biomedical Technology Regulations in China

  • 29 March, 2019
  • In response to draft regulations in China on gene editing and other potentially risky biomedical technologies, the ISSCR has submitted comments to the the country's National Health Commission Medical and Medical Administration Bureau.
    Full story
  • ISSCR Testimony in U.S. Congress Regarding Need for Fetal Tissue Research

  • 13 December, 2018
  • In written and oral testimony before the U.S. House of Representatives Oversight and Government Reform Committee today, former ISSCR president Sally Temple describes fetal tissue research as essential in studying and developing therapies for cancer, HIV, Zika, tuberculous, and other devastating diseases.
    Full story
  • ISSCR Comments on Reports of Chinese Scientists Performing Genome-Editing During Fertility Treatment

  • 26 November, 2018
  • Reports indicate that scientists in China have used CRISPR-mediated genome editing during in vitro fertilization to modify the genetic material of two embryos that were subsequently implanted into a patient, leading to the birth of two babies. As ISSCR and a number of other organizations have previously stated, the use of nuclear genome editing technologies, such as CRISPR, during fertility treatment is premature and should not be attempted at this time.
    Full story
  • ISSCR Comments to FDA Regarding ClinicalTrials.gov

  • 21 November, 2018
  • In a letter to the U.S. Food and Drug Administration (FDA), the ISSCR commented on proposed industry guidance for "Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank."
    Full story
  • ISSCR Applauds FDA, FTC for Holding Deceptive Stem Cell Clinics Accountable

  • 16 November, 2018
  • The U.S. Food and Drug Administration has issued a warning letter to StemGenex of San Diego after an investigation found its cellular therapy does not conform with good manufacturing practice requirements, is being illegally marketed to treat conditions for which it has not been proven safe or effective, and is putting patients at risk.
    Full story
  • ISSCR Comments on Horizon Europe

  • 2 October, 2018
  • The ISSCR has responded to the European Commission proposal and the European Parliament's amendments for Horizon Europe, the seven-year research and innovation funding program to follow Horizon 2020.
    Full story
  • ISSCR Responds to U.S. Department of Health and Human Services Decision Regarding Fetal Tissue Research

  • 27 September, 2018
  • The ISSCR is troubled by the HHS decision to “conduct a comprehensive review of all fetal tissue research.” The directive appears to come after intensive lobbying efforts by special interest groups with the goals of delaying or curtailing scientific research that relies on fetal tissue.
    Full story
  • ISSCR Opposes Proposal to Restrict Fetal Tissue Research

  • 14 June, 2018
  • 6/14/2018 2:00:00 PM

    The ISSCR opposes the U.S. House of Representatives proposal to ban federal funding for fetal tissue research. ISSCR President Hans Clevers released a statement on the issue.
    Full story
  • ISSCR Responds to President Trump Signing 'Right to Try' Law

  • 4 June, 2018
  • 6/4/2018 4:00:00 AM

    The ISSCR is disappointed with the enactment of the ‘Right to Try’ law. Along with more than 100 patient and research groups opposing the bill, we believe it will put patients at risk and undermine the effective FDA Expanded Access Program already in place to give seriously ill patients access to experimental treatments.
    Full story
  • ISSCR Applauds Federal Injunctions Against Stem Cell Clinics

  • 10 May, 2018
  • The ISSCR is pleased that federal prosecutors in the U.S. have taken action to halt the marketing and delivery of unproven stem cell treatments at clinics they allege are operating outside of FDA regulation.
    Full story
  • 'Right to Try' Legislation in U.S. House of Representatives is Narrowly Defeated; ISSCR Opposed

  • 12 March, 2018
  • The legislation would have put patients at risk, slowed the development of effective stem cell therapies, and blocked the Food and Drug Administration (FDA) from access to crucial data about the safety and effectiveness of new medical treatments.
    Full story
  • ISSCR 2018 Election Results

  • 12 March, 2018
  • The ISSCR is pleased to announce the results of its 2018 leadership election. On behalf of all members, we extend congratulations to newly-elected officers and board members.
    Full story
  • ISSCR Releases Guidebook to Evaluate Cell Therapy Trials

  • 15 February, 2018
  • The ISSCR is pleased to announce the release of “Stem Cell Based Clinical Trials: Practical Advice for Physicians and Ethics / Institutional Review Boards,“ a guidebook providing background and fundamental questions for clinicians and review boards to ask when considering running or reviewing early phase, cell-based clinical trials. The guide was developed by practicing physician-scientists and stem cell professionals on the ISSCR’s Clinical Translation Committee.
    Full story
  • ISSCR Members Asked to Vote for Future Leaders

  • 17 January, 2018
  • The election is open for several ISSCR leadership posts, and members and trainee members are eligible to cast ballots in the election. Voting closes 5 February, 2018.
    Full story
  • ISSCR Announces Two New Science Communications & Education Managers

  • 4 January, 2018
  • The ISSCR has selected Christopher Barry, PhD, and Julie Perlin, PhD, to be Science Communications & Education Managers, beginning 3 January, 2018.
    Full story
    View All ISSCR News